Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Investor Presentation (July 2026)
10 slides from Little Green Pharma's investor presentation, July 2026
Slide 1: Path to Global Leadership
LGP C ANNATREK G ROUP Path to Global ASX : LGP Leadership Building a premier global vertically integrated medicinal cannabis company – from Australian Investor Presentation cultivation to European markets JULY 2026
Slide 2: Disclaimer
Disclaimer Summary Information No liability An investment in the Company is considered Past performance This presentation has been prepared by Little No securities regulatory author ity or similar authority has to be speculative in nature. Past p erfor mance is no guarantee of future Gr een Pharma L
Slide 3: Merger Complete
Merger Complete Recent merger has created one of the world's largest pure-play medicinal cannabis businesses Little Green Pharma Cannatrek • Largest GMP cannabis facility in Europe • One of the largest AU-GMP certified (Denmark - 21,500m² cultivation, 4,000m² manufacturing facilities in Australia po
Slide 4: Financial Overview
Financial Overview Pro-forma combined financials based on FY25 audited results $112m $13m $15m >$136.7m P RO -FORM A REV ENUE P RO -FORM A A DJ. E BI TD A C AS H NET A SS ET S FY25 combined¹ FY25 combined² At merger date³ Combined balance sheet⁴ STANDALONE CONTRI BU TIONS Company Revenue1 Adj. EBITD
Slide 5: Synergy Capture & Strategic Investment
Synergy Capture & Strategic Investment A three-stage strategy to build and scale globally Foundation & Build Scale synergy capture By end of FY27 FY28 + FY29 The next 90 - 180 days • Complete operational integration Invest in EU and UK growth initiatives: • Complete second stage Danish of LGP and Ca
Slide 6: Leadership Team – Delivering the Plan
Leadership Team – Delivering the Plan Operating leaders driving integration and performance across the combined group Paul Long Jason Rance Alistair Warren Group Chief Executive Officer & Director Chief Executive Officer (Australia) General Counsel & Company Secretary Architect of LGP's European exp
Slide 7: Core Markets Focus
Core Markets Focus Our primary focus is on three core medicinal cannabis markets AUST RALIA GER MANY UN IT ED K INGD OM $1bn+ 900,000+ 140,000+ Market passed $1 billion in sales Patient count climbed from 250,000 Patient count is expected to climb to at end of CY2025¹ to nearly 900,000 in 13 months
Slide 8: Strategic Framework
Strategic Framework A six-pillar strategic framework guiding the LGP Cannatrek Group's path to global leadership PI LLA R 1 PI LLA R 2 PI LLA R 3 Operational excellence to fund growth Denmark: Our European edge Hold serve in Australia Rigorous cost management and resource Board-approved investment t
Slide 9: Shareholder Value Creation
Shareholder Value Creation The convergence of market timing, merger scale and operational readiness creates a compelling entry point FIVE CA TA L YST S FO R VA L UE C RE AT IO N Profitable foundation: Unlike most cannabis companies globally, the combined group is profitable at the EBITDA level and c
Slide 10: Q&A
ASX : LGP Q&A Paul Long, Group CEO and Director A world of difference investor.littlegreenpharma.com
Little Green Pharma — Investor Presentation (July 2026) on 6ix